Towards precision oncology in RET-aberrant cancers.
a The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Vivek
V
Subbiah
a The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Jason
J
Roszik
D019008:Drug Resistance, Neoplasm / Q000187:drug effects / Q000235:genetics; D006801:Humans; D008495:Medical Oncology; D009154:Mutation / Q000235:genetics*; D059645:Mutation Rate; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics*; D057285:Precision Medicine; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D051096:Proto-Oncogene Proteins c-ret / Q000235:genetics*; D017422:Sequence Analysis, DNA
D047428:Protein Kinase Inhibitors; D051096:Proto-Oncogene Proteins c-ret
NGS; RET; TCGA; next generation sequencing; precision oncology